CompletedNCT00300846
A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients
Medication studyAges 18–65Multiple countriesSchizophrenia
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Graz and 56 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateDecember 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 200
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- France, United Kingdom, Switzerland, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00300846
- Official title
Show the full official title
A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment With Aripiprazole in Patients With Schizophrenia.
Recruitment & locations
CompletedGraz, Austria · Innsbruck, Austria · Vienna, Austria
56 more locations
- Brno-Bohunice, Czechia
- Hradec Králové, Czechia
- Litoměřice, Czechia
- Opava, Czechia
- Prague, Czechia
- Helsingin Kaupunki, Finland
- Tampere, Finland
- Turku, Finland
- Brumath, France
- Bully-les-Mines, France
- Clermont-Ferrand, France
- Limoges, France
- Lyon, France
- Nîmes, France
- Paris, France
- Rennex Cedex 7, France
- Sotteville-lès-Rouen, France
- Augsburg, Germany
- Berlin, Germany
- Duisburg, Germany
- Haar, Germany
- Heidelberg, Germany
- Mannheim, Germany
- Budapest, Hungary
- Szolnok, Hungary
- Krakow, Poland
- Leszno, Poland
- Skorzewo, Poland
- Torun, Poland
- Warsaw, Poland
- Soweto, South Africa
- Vereeniging, South Africa
- Durban, South Africa
- Bellville, South Africa
- Cape Town, South Africa
- Bromma, Sweden
- Falköping, Sweden
- Linköping, Sweden
- Luleå, Sweden
- Malmö, Sweden
- Solna, Sweden
- Uppsala, Sweden
- Varberg, Sweden
- Västra Frölunda, Sweden
- Bern, Switzerland
- Antalya, Türkiye
- Istanbul, Türkiye
- Izmir, Türkiye
- Exeter, United Kingdom
- Teignmouth, United Kingdom
- Welwyn Garden City, United Kingdom
- Hull, United Kingdom
- Dundee, United Kingdom
- London, United Kingdom
- Czechia
- Türkiye
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including aripiprazole and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...